252722-52-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE is used as a pharmaceutical compound for its potential therapeutic applications in treating various diseases and conditions. Its unique structure and biological activities make it a valuable candidate for the development of new drugs and therapies.
Used in Cancer Treatment:
In the field of oncology, 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE is used as a potential anticancer agent. Its specific biological activities and interactions with cellular targets may contribute to the inhibition of tumor growth and progression, offering a new avenue for cancer treatment.
Used in Neurological Disorders Treatment:
4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE is also used as a potential therapeutic agent for neurological disorders. Its ability to modulate specific biological pathways and targets in the nervous system may provide new insights and treatment options for various neurological conditions.
Used in Drug Development Research:
In the realm of drug development, 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE serves as a subject of interest for further research. Its unique structure and potential biological activities are being investigated to understand its mechanisms of action and to develop new drugs with improved efficacy and safety profiles.

InChI:InChI=1/C10H13N5/c1-2-12-9-8(1)10(14-7-13-9)15-5-3-11-4-6-15/h1-2,7,11H,3-6H2,(H,12,13,14)

Upstream product

• 1248587-70-3 tert-butyl 4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 110-85-0 piperazine 

Relevant academic research and scientific papers

Efficient photocaging of a tight-binding bisubstrate inhibitor of cAMP-dependent protein kinase

Photocaging of a tight-binding bisubstrate inhibitor of cAMP-dependent protein kinase (PKA) with a nitrodibenzofuran-based group fully abolished its inhibitory potency. The affinity difference between the photocaged and the active inhibitor was over 5 orders of magnitude. The photocaged inhibitor disrupted the PKA holoenzyme in cell lysates upon photolysis under a 398 nm LED.

Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity

Targeting of Akt has been validated as a well rationalized approach to cancer treatment, and represents a promising therapeutic strategy for aggressive hematologic malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably, 10h exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells. Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3β and S6 in Jeko-1 cells.

AXL KINASE INHIBITORS

Axl kinase inhibitory compounds are disclosed, as well as compositions and methods of using the same in the treatment of cancer and other conditions mediated by and/or associated with Axl kinase.

Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use

Novel pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 as well as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases are described.